Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement

ABSTRACTBackground and objectives: Multiple reforms aimed at improving the Chinese population’s health have been introduced in recent years, including several designed to improve access to innovative drugs. We sought to review current factors affecting access to innovative drugs in China and to anti...

Full description

Saved in:
Bibliographic Details
Main Authors: Bérengère Macabeo, Liam Wilson, Jianwei Xuan, Ruichen Guo, Petar Atanasov, Linda Zheng, Clement François, Philippe Laramée
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Journal of Market Access & Health Policy
Subjects:
National Reimbursement Drug List
innovative drug access
pricing
reimbursement
decision making
health technology assessment
Online Access:https://www.tandfonline.com/doi/10.1080/20016689.2023.2218633
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items